smoothened

SAG hydrochloride (912545-86-9(free base)) (Smoothened Agonist HCl) 可作为 SMO 激动剂。

SAG (Smoothened Agonist) 是一种 Smo 受体激动剂 (EC50=3 nM)，具有细胞渗透性和选择性。SAG 可以直接结合 Smo 螺旋束调节 Smo 活性，可以活化 Hedgehog 信号通路。

Halcinonide (Halciderm) 是一种糖皮质激素，可用于局部皮肤感染的研究。

AZD8542 是 Smoothened (SMO) 的拮抗剂，也是一种 Hedgehog (Hh) 通路拮抗剂，具有抗癌抗增殖活性，可抑制生物体内肿瘤的生长，可用于研究前列腺癌和结肠癌。

SMO-IN-2 是一种有效的 smoothened (SMO) 抑制剂，对 hedgehog (Hh) 信号传导有抑制作用。SMO-IN-2 对人髓母细胞瘤细胞系 显示出抗增殖活性和抗癌活性。SMO-IN-2 可用于研究癌症。

CUR61414 hydrochloride 是属于氨基脯氨酸类化合物的小分子。CUR61414 hydrochloride 是一种细胞渗透性的 Hedgehog 信号通路抑制剂(IC50= 100-200 nM)，可选择性结合 Smoothened (Smo, Ki= 44 nM)。CUR61414 hydrochloride 可以诱导癌细胞凋亡 (apoptosis) 而不影响非癌症细胞。

GI-560192 (RL-0070933) 是一种有效的纤毛调节剂。GI-560192 通过 hedgehog 信号通路调节 smoothed (Smo) 向初级纤毛的易位和/或积累。

20(S)-Hydroxycholesterol (20α-Hydroxycholesterol) 是平滑 (smo) 癌蛋白的变构激活剂。

CUR61414 是 Hedgehog 信号通路的细胞渗透性抑制剂 (IC50 = 100-200 nM)，并选择性地结合 smoothened (Ki = 44 nM)。

LEQ506 是一种 Smo 抑制剂，对 hSmo 和 mSmo 的 IC50 分别为 2 nM 和 4 nM。

Cyclopamine (11-Deoxojervine) 是Hedgehog 通路的拮抗剂，细胞实验中IC50=46 nM。它还是选择性Smo 抑制剂。

SANT-1 是Smo 拮抗剂，能够抑制Hedgehog 通路，在 Shh-LIGHT2 和 SmoA1-LIGHT2 实验中，得到的IC50值分别为 20 nM 和 30 nM。

Purmorphamine (Shh Signaling Antagonist VI) 是平滑受体激动剂，EC50为 1 μM。它阻止 BODIPY-cyclopamine 与 Smo 结合。它也是成骨细胞分化的诱导剂。

HhAntag 是高效的、特异性的、具有口服活性的 Hh 通路的SMO 拮抗剂。

PF-5274857 (PF-5274857 free base) freebase 是有效的、具有口服活性的、选择性的、可透过血脑屏障的 Smo 拮抗剂，其 IC50=5.8 nM，Ki=4.6 nM。它有用于包括激活的 Hh 途径驱动的脑肿瘤和脑转移在内的多种肿瘤的研究潜力。

GSA-10是新型的喹啉甲酰胺衍生物，有效激动平滑受体剂，EC50为 1.2 μM。它作用于Smo，促进多能间充质干细胞分化为成骨细胞。它介导 Hedgehog 信号传导，这可能对癌症疾病的再生医学具有研究意义。

MRT 10 是一种七跨膜平滑受体 (Smo) 拮抗剂，通过多种 Hedgehog (Hh) 测定，其IC50=0.65 μM。它与Smo 受体结合的位点是 Bodipycyclopamine。它可用于研究癌症。

MK-4101 是一种 SMO 拮抗剂 ，对 293 细胞的 IC50为 1.1 µM。它也是一种 hedgehog 信号通路的有效抑制剂 ，对小鼠细胞和KYSE180 食管癌细胞的IC50分别为 1.5 µM 和 1 µM。它能抗肿瘤，抑制肿瘤细胞增殖并诱导细胞凋亡。

MRT-81 是一种人和啮齿动物 smoothened 受体的有效拮抗剂，能够抑制 hedgehog 的活性，在 Shh-light2 细胞中的IC50值为 41 nM。它可用于研究癌症。

MRT-14 是有效的 Smo 拮抗剂。Smo 是参与 Hedgehog 形态发生素信号转导的主要成分。MRT-14 在研究与异常 Hh 信号传导相关的多种癌症方面有价值。

IHR-1 是一种Smo 拮抗剂，不能透过细胞膜。

SMANT hydrochloride (N-(4-bromophenyl)-3-(3,5-dimethylpiperidin-1-yl)propanamide hydrochloride) 是一种 Smoothened 积聚的拮抗剂。

MRT-83 是一种 Smo 拮抗剂，其IC50值在纳摩尔级别。它能够抑制 Hedgehog 信号通路。

Sonidegib diphosphate (LDE225 diphosphate) 是 Smo 的选择性拮抗剂，能够抑制鼠 Smo (IC50:1.3 nM)和人 Smo (IC50:2.5 nM)。

BMS-833923 (XL-139) 是一种口服生物可利用的 Smoothened 拮抗剂，以剂量依赖性方式抑制 BODIPY cyclopamine 与 SMO 的结合，IC50为21 nM。

Taladegib (LY2940680) 是smoothened 受体拮抗剂。

DY131 (DY-131) 是选择性的 ERRγ 和 ERRβ 激动剂，对 ERRα，ERα 和 ERβ 无效。它对Smo 的信号传导具有抑制作用。

Sonidegib (Erismodegib) 是一种Smo 的选择性拮抗剂，能够抑制鼠 Smo (IC50:1.3 nM)和人 Smo (IC50:2.5 nM)。

ALLO-2 是一种 Smo 耐药突变体的拮抗剂。在TM3-Gli-Luc 细胞中，它可抑制Smo 激动剂Hh-Ag1.5诱导的荧光素酶表达，其IC50=6 nM。

S1PL-IN-31是一种鞘氨醇-1-磷酸(S1P)裂解酶的抑制剂(IC50 = 210 nM)，同时也是Smoothened(Smo)受体的对抗剂(IC50 = 440 nM)。在体内，S1PL-IN-31 (每天2 mg/kg)能够防止实验性自身免疫性脑炎(EAE)模型大鼠中，由髓鞘少突胶质细胞糖蛋白(MOG)肽段MOG29-152诱发的颈部及胸部淋巴细胞渗透和神经肌肉虚弱。该化合物降低了大鼠的淋巴细胞总数及CD4+ T细胞、CD8+ T细胞和B细胞的水平。S1PL-IN-31 (每天3及10 mg/kg剂量)在雄性和雌性大鼠心脏和淋巴结中增加了S1P水平，并且在雌性大鼠中降低了心率。

LEQ506 is an orally bioavailable small-molecule Smoothened antagonist. It also has a potential antineoplastic activity.

Saridegib is an effective and specific inhibitor of Smoothened and a key signaling transmembrane protein in the Hedgehog pathway.

HPI-1 (hydrate) is a Hedgehog (Hh) pathway inhibitor that suppresses signaling through Sonic Hh (IC50= 1.5 μM) without significantly affecting Wnt signaling (IC50≥ 30 μM).1HPI-1 suppresses Hh activation induced by loss of Suppressor of Fused or by Gli overexpression, suggesting action at posttranslational modification of Gli protein or at the interaction of Gli with a co-factor.1HPI-1 (hydrate) also inhibits signaling through the oncogenic Smoothened (Smo) mutant SmoM2 in neuron precursors, preventing cell proliferation.1 1.Hyman, J.M., Firestone, A.J., Heine, V.M., et al.Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockadeProceedings of the National Academy of Sciences of the United States of America106(33)14132-14137(2009)

Hh-Ag1.5 (SAG-1.5) 是一种高效的 Hedgehog (Hh) 激动剂(EC50： 1 nM)和Smoothened (Smo)受体激动剂，对Smo的 EC50 为 1 nM、 Ki值在 0.5 和 2.3 nM 之间。Hh-Ag1.5 介导的重编程打破了非损伤肝脏干细胞的静止状态，从而挽救了肝衰竭。Hh-Ag1.5 诱导 hiPSCs 分化为皮肤前体细胞、脊髓运动神经元和脊髓感觉神经元。

Jervine (Jerwiny) 是一种有效的刺猬 (Hh) 抑制剂(IC50:500-700 nM)。它是一种天然致畸性甾体生物碱，来自于 Veratrumalbum 的根茎，具有抗炎和抗氧化作用。

SMO-IN-4（Compound 24），一种smoothened拮抗剂，具有口服活性，IC50为24 nM，显示出抗肿瘤活性。

NL-103 is a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations. NL-103 comprises structural elements of Hh pathway inhibitor vismodegib, and histone deacetylase (HDAC) inhibitor vorinostat. NL-103 simultaneously and significantly inhibited both HDACs and Hh pathway. Importantly, NL-103 effectively overcame vismodegib resistance induced by Smoothened point mutations. Moreover, NL-103 significantly downregulated the expression of Gli2 which plays an important role in Hh pathway. NL-103 may be a promising compound for clinical development as a more effective Hh pathway inhibitor.

Cyclopamine-KAAD is a potent inhibitor of hedgehog signaling with an IC50 value of 20 nM in a Shh-LIGHT2 assay. It blocks binding of BODIPY-cyclopamine to cells expressing Smoothened (Smo) in a dose-dependent manner. Cyclopamine-KAAD is cell-permeable and binds to SmoA1 to promote its exit from the endoplasmic reticulum. It inhibits the invasion and migration (45.9 and 43.3% inhibition, respectively) of Bel-7402 hepatocarcinoma cells and decreases the expression of nuclear glioma-associated oncogene 1 (Gli1) and cytosolic MMP-9, pERK1, and pERK2 proteins in a dose-dependent manner. Cyclopamine-KAAD also increases TRAIL-mediated cell death in NCH82 and NCH89 human glioblastoma cultures and upregulates expression of the death receptors DR4 and DR5 in LN229 and U251 glioma cells.

MRT-83 (hydrochloride) is a potent antagonist of the Smoothened (Smo) receptor, effectively inhibiting the Hedgehog (Hh) signaling pathway and BODIPY-cyclopamine binding to human Smo. With its potential applications in the study of cancer disease, MRT-83 (hydrochloride) demonstrates promising prospects for research purposes.

Smoothened (SMO) is a GPCR-like receptor which, with Patched, mediates hedgehog signaling to regulate gene expression through the Gli transcription factors. 20(S)-hydroxy Cholesterol (20(S)-OHC) is an oxysterol which binds SMO and activates hedgehog signaling (EC50 = 3 μM), and this activation is selective for the nat-20(S)-OHC enantiomer. Nat-20(S)-OHC synergizes with the SMO agonist SAG, suggesting an allosteric effect. Nat-20(S)-yne is a form of nat-20(S)-OHC with a terminal alkyne group, which can be used in linking reactions known as click chemistry. Click chemistry involves highly dependable and specific azide-alkyne bioconjugation reactions and can be used to capture or immobilize bioactive molecules. Thus, nat-20(S)-yne has been conjugated with magnetic beads to demonstrate that nat-20(S)-OHC directly binds SMO.

Potent fluorescent Smo antagonist (IC50 = 100 nM). Non-fluorescent analog also available. Fan et al (2014) The Hedgehog pathway effector smoothened exhibits signaling competency in the absence of ciliary accumulation. Chem.Biol. 21 1680 PMID:25484239

SMO-IN-3 是 smoothened (SMO) 对有效抑制剂，能够作用于 hedgehog (Hh) 信号通路 (IC50: 34.09 nM)。SMO-IN-3 能够抑制人髓母细胞瘤细胞系 Daoy 的增殖，表现出抗癌作用。

Smoothened (Smo) receptor antagonist

(Rac)-SAG, an isoform of SAG, is a potent Smoothened (Smo) receptor agonist (EC₅₀ = 3 nM; Kd = 59 nM) that activates the Hedgehog signaling pathway and counteracts Cyclopamine's inhibition of Smo [1] [2] [3].

7-Keto-25-hydroxy Cholesterol, an oxysterol and proposed metabolite of 7-keto cholesterol and 7-dehydro cholesterol, binds to and activates Smoothened (Smo) at the conserved extracellular cysteine-rich domain (CRD) in a reporter assay. Additionally, it enhances the number of EGF high affinity binding sites in normal rat kidney (NRK) cells.

MRT-92 is a potent and selective Smoothened (Smo) receptor inhibitor. MRT-92 displays subnanomolar antagonist activity against Smo in various Hh cell-based assays. MRT-92 inhibits rodent cerebellar granule cell proliferation induced by Hh pathway activation through pharmacologic (half maximal inhibitory concentration [IC50] = 0.4 nM) or genetic manipulation. Smo is the target of anticancer drugs that bind to a long and narrow cavity in the 7-transmembrane (7TM) domain.

Potent Smo antagonist (IC50 = 5 nM). Attenuates the leukemia-initiation potential of AML cells in a serial transplantation mouse model. Also eliminates self-propagation capacity of AML cells. Munchhof et al (2011) Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med.Chem.Lett. 3 106 PMID:24900436 |Fukushima et al (2016) Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci. 107 1422 PMID:27461445 |Giordani et al (2016) The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells. Oncotarget 7 55313 PMID:27486815

TPB15 是一种口服具有活力的 Hh(Hedgehog) 信号抑制剂。TPB15 可以明显阻滞 MDA-MB-468 细胞周期，并诱导其凋亡。TPB15 阻断 Smo(Smoothened) 转位到纤毛中，减少 Smo 蛋白和 mRNA 表达。TPB15 对下游调控因子胶质瘤相关癌基因1 (Gli1) 的表达表现出抑制作用。TPB15 具有较好的抗肿瘤作用，且毒性较低。